CEL-SCI Corporation Releases Letter to Sh...( VIENNA Va. Dec. 12 /- The following ...)

VIENNA, Va., Dec. 12 /PRNewswire-FirstCall/ -- The following letter is being released by CEL-SCI CORPORATION (NYSE Alternext US: CVM) to its shareholders:

Dear Fellow Shareholders:

Recently we have had two pieces of important news for CEL-SCI Corporation and its shareholders. First, the U.N. World Health Organization's Agency for Research on Cancer report, in reference to the "cancer burden" wrote that "the global burden doubled in the last 30 years of the 20th Century, and it is estimated that this will double again between 2000 and 2020 and nearly triple by 2030". Cancer will soon become the Number One killer in the world, ahead of heart disease. Those increases are much greater than many people had expected and clearly make our non-toxic Multikine cancer product even more important to develop. Second, we need your help with a legislative proposal advocated by the Biotechnology Industry Organization (BIO) which would help CEL-SCI bring Multikine to market faster. Last, what percentage of people do you think will get cancer and how many of them will die from it? The answer may shake you (see below).

    In this letter I also want to review the general status of our Multikine cancer drug:

        1. In the last few months we have hit major milestones.  We signed a
           Multikine licensing agreement with Teva Pharmaceuticals, a
           multinational pharmaceutical company, which will participate in
           and pay for part of our Phase III trial, we took delivery of our
           new manufacturing facility in Baltimore (see the pictures at
           www.cel-sci.com and click on Updated Pictures of Manufacturing
           Facility), and we extended our existing Multikine partnership with
           Orient Europharma (OEP) of Taiwan to cover a larger territory.
           OEP, like Teva, will participate in and pay for part of the Phase
           III clinical t
'/>"/>
SOURCE  CEL-SCI Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 
Related biology technology :

1. CEL-SCI to Present at the Noble Financial Conference
2. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
3. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
4. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
5. CEL-SCI Takes Delivery of New Manufacturing Facility
6. Updated Pictures of CEL-SCI Manufacturing Facility Available Online
7. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. BioElectronics Corporation Announces Singapore and Malaysia Sales